Clinical trial
A Multicenter Open-Label Non-Comparative Dose Escalation Study (Phase 1) of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 (JSC BIOCAD, Russia) in Patients With Relapsing-Remitting Multiple Sclerosis
NCT03551275 is registered in ClinicalTrials.gov with Biocad as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter Open-Label Non-Comparative Dose Escalation Study (Phase 1) of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 (JSC BIOCAD, Russia) in Patients With Relapsing-Remitting Multiple Sclerosis
- Lead sponsor
- Biocad
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 22, 2018
- Completion date
- March 28, 2019
- Enrollment
- 24 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.